Free Newsletter
New vaccine/chemo combo effective in cancer study
New trial data shows that the combination of a chemotherapy drug and a new vaccine significantly prolonged the survival of patients with glioblastoma, the aggressive brain cancer that now afflicts Senator Ted Kennedy. The therapy is the brainchild of Houston neurosurgeon Samuel Hassenbusch, who became the first of 23 patients to enroll in the study after he was diagnosed with the disease. He died earlier this year.
In a surprise, the researchers found that the chemotherapy did not interfere with the vaccine. In fact, the chemotherapy evidently enhanced the vaccine's effect.
"I'm biased, but this is some of the best data we've ever seen," Duke University neurosurgean Dr. John Sampson told the Houston Chronicle. "It appears very promising for a cancer where there's been little hope."
- read the article in the Houston Chronicle
Related Article:
Kennedy's best hope may lie in cancer vaccine trial
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
